MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
Haystack MRD test detects minimal residual disease in stage 2 colorectal cancer patients post-surgery, using circulating tumor DNA (ctDNA) for less invasive monitoring. The FDA's breakthrough device ...
SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated “RaDaR ST represents an important advancement in MRD testing, a ...
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing SAGA ...
BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares jumped 10% after the company announced strategic agreements with Fidelion Diagnostics to jointly commercialize VitaGuard, a next-generation liquid biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results